Sonoma Pharmaceuticals, Inc. · NASDAQ:SNOA
Sonoma Pharmaceuticals — Investor Presentation (April 2025)
31 slides from Sonoma Pharmaceuticals's investor presentation, Apr 28, 2025
Slide 1: Sonoma Pharmaceuticals, Inc. Investor Presentation April 2025
Sonoma Pharmaceuticals, Inc. Investor Presentation April 2025
Slide 2: Legal Disclaimers
Legal Disclaimers or INVESTOR PRESENTATION This communication is for informational purposes only. The information contained herein does not purport to be all - inclusive. The data contained herein is derived from various internal and external sources. No representation is made as to the reasonablene
Slide 3: About Sonoma
About Sonoma Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non - toxic disinfectan
Slide 4: Hypochlorous Acid Industry Leader
Hypochlorous Acid Industry Leader Hypochlorous Acid Industry Leader 22 U.S. FDA clearances as 510(k) medical devices, transition to MDR completed for all revenue - producing products, and extensive worldwide regulatory clearances Utilized on millions of patients worldwide without a single report of
Slide 5: Sonoma's Microcyn Technology
Sonoma’s Microcyn ® Technology Patented, Stabilized Triple - Action Topical Technology • HOCl kills microbes including bacteria, fungi and viruses while assisting healing • Relieves pain and itch • Improves wound care by cleaning and moistening the wound and peri - wound area • Safely manage skin ab
Slide 6: Sonoma's Microcyn Technology: Safety and Industry Leader
Sonoma’s Microcyn ® Technology Unparalleled Safety • No drug - to - drug interaction or contraindications • Millions of patients treated worldwide without a single report of serious adverse effect • 30+ human clinical trials with over 1,500 patients • Products contain all - natural hypochlorous acid
Slide 7: Research articles and case and clinical studies
Over 100 research articles and case and clinical studies showcasing both the efficacy and safety of our Microcyn ® technology • Dermodacyn® Disinfecting solution study on viability of SARS - CoV - 2, see https:// www.sciencedirect.com/science/article/pii/S019567012030339X • Endocyn® study on cellula
Slide 8: Wide Range of Applications
Wide Range of Applications Wound Care Dermatology Eye Care Oral and Dental Care Animal Health Care Surface Disinfectants Podiatry 8 Senior Care
Slide 9: Our Wound Care Business is Growing in the U.S. and Internationally
Our Wound Care Business is Growing in the U.S. and Internationally • Celebrating 20 years of selling wound care • In August 2024, we added Medline Industries, LP as a U.S. distributor for our wound care products – Medline is one of the largest medical supply distributors in the United States • In Oc
Slide 10: Industry-Leading Safe and Effective Dermatology Products
Industry - Leading Safe and Effective Dermatology Products • Products to relieve symptoms of atopic dermatitis, reduce scarring, and for daily skin care • Line of office dispense products targeting growing med spa market • Eczema seal of approval • All natural ingredients • No harmful chemicals • OT
Slide 11: Expanded Eye Care Product Line
Expanded Eye Care Product Line • Sonoma has the strongest FDA indications for eye care in the HOCl industry • OTC and prescription eye care sold into multiples channels • Strong CE Mark for eye care sales in the EU • Animal health eye care sold in major chains including PetSmart and Tractor Supply 1
Slide 12: Robust U.S. and International Distribution Network
Robust U.S. and International Distribution Network OVER 40 GLOBAL PARTNERS AND GROWING We continue to: • Expand our presence in new markets by replicating what works in existing markets • Add new distribution partners and grow existing relationships • Co - develop innovative new products with partne
Slide 13: Cutting Edge Manufacturing
• 57,153 square foot state - of - the - art facility • ISO 9001, ISO 13485 and cGMP certified • MOH, KFDA, SFDA, KSA, TGA, EN, Biocide and numerous other national listings and approvals • Shipping to over 55 countries, with multiple methods for shipments • Highly trained staff of 162 employees • Add
Slide 14: Manufacturing Facility
Manufacturing Facility Ti
Slide 15: Growth Strategy
Continue to introduce new high margin products Manufacturing capabilities can support significant future growth, leading to improved margins overall • Launch new applications of Sonoma’s Microcyn® technology for consumer - focused products, including in the dermatology and aesthetic space Growth Str
Slide 16: New Market Opportunities
New Market Opportunities Sonoma is expanding its partnerships and product offerings in the eye care, all - natural skin care, medical spa and animal health care industries. • The global eye care market size was estimated at USD $70.78 billion in 2023 and is projected to grow at a compound annual gro
Slide 17: Introduction of new products using our Microcyn technology
Introduction of new products using our Microcyn ® technology 17 • In December 2024, we announced the relaunch of our prescription eye care product, Acuicyn ® , our prescription dermatology products Celacyn ® , Levicyn ® and Epicyn ® , and our over - the - counter Lasercyn ® Dermal Spray and Lasercyn
Slide 18: Expanding commercialization opportunities by investing in R&D
Expanding commercialization opportunities by investing in R&D • We successfully transitioned all of our commercialized products in Europe, including eye care , wound care , scar gel , acne products and atopic dermatitis products to the new European Union (EU) Medical Device Regulation (MDR) . • Our
Slide 19: Continuously expanding our distributor network
Continuously expanding our distributor network 19 • In April 2025, we announced the launch our of acne products in the U.K. through a leading health and beauty retailer and pharmacy chain. • In January 2025, we partnered with WellSpring Pharmaceutical Corporation for the sale of our Microcyn technol
Slide 20: Management
Management Amy Trombly CEO Amy Trombly is 20 our Chief Executive Officer and also serves on our Board of She counseled public Directors. companies corporate for over two decades in and securities law and mergers and acquisitions, including as the owner and manager of Trombly Business Law, PC . In he
Slide 21: Key Financial Metrics
Key Financial Metrics 21 Nine months ended December 31, 2024 - » Revenues increased 13% compared to same period FY 2024 » Net loss improved $1.1 million , or 29% , compared to same period FY 2024 Three months ended December 31, 2024 - » Revenues increased 14% compared to same period in FY 2024 » Pos
Slide 22: APPENDIX: Product Portfolio
APPENDIX: Product Portfolio
Slide 23: Diverse Product Portfolio
Diverse Product Portfolio United States Reliefacyn Regenacyn Podiacyn Lumacyn = Microcyn Rx = Acuicyn Nanocyn sun, Retlefac TERE: cocniyectene — Chriyngiier Sn Wound Caro Eyelid 8 Eelnh Hapa Gade pa cs Disinfectant cyt i Celacyn Pediacyn Microcyn OTC Rejuvacyn _Lasercyn aac eh Ee CPi eee | Ce any FE
Slide 24: U.S. Dermatology
ES U.S. Dermatology + Office dispense products exclusively for skin care professionals + Generates highest margins for Sonoma + Focused marketing to med spas and dermatology offices, which can resell products to their clients for a substantial margin —— ee
Slide 25: U.S. Animal Health Care
U.S. Animal Health Care MicrocynAH ® family of advanced animal healthcare products, safe to use on pets and livestock, and perfect for hot spots, pink eye, scratches, skin rashes and ulcers, cuts, burns, post - surgical sites, irritated skin and lacerations. • Sold in national pet - store retail cha
Slide 26: EU Products
EU Products Solutions that work naturally for everybody mos “oa oles vent voce elie Microdacyn60° : =| MicrocynAH® = Wound Care ii I c| Animal Health Care ie = gS
Slide 27: Direct-to-consumer products available through Shopify, Amazon
Direct-to-consumer products available through Shopify, Amazon and Amazon EU 5 8 us. Products EU Products
Slide 28: Middle East
Middle East Microsafe Disinfectant & Sanitizer
Slide 29: Asia
Singapore, Malaysia, Thailand, Indonesia Wound Care South Korea BioDerm Biodacyn60 Wound Care Hong Kong Microdacyn60 Oral Care China Microcyn The Philippines Microdacyn MicrocynAH ® Asia 29
Slide 30: Latin America, Australia & New Zealand
Gramacyn Kit for Acne Skin Latin America T Epicyn reat Scars Right from the Start Australia & New Zealand 30
Slide 31: Thank You
THANK YOU Sonoma Pharmaceuticals Inc. 5445 Conestoga Court, Suite 150 Boulder, CO 80301 United States of America Phone: 1 - (800) 759.9305 Email: busdev@sonomapharma.com Website: www.sonomapharma.com NASDAQ: SNOA
Sonoma Pharmaceuticals — Investor Presentation (April 2025) on 6ix